ClinicalTrials.gg
CompletedNCT02442284Updated Oct 16, 2017Results posted

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

A Phase 3 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and Ribavirin in Chronic Hepatitis C, Cirrhosis and Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing ombitasvir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. ombitasvir · Hepatitis C, Chronic.

Enrollment
12th of 19
99 · median 148
Started
2015
with 6 others
Phase 3
10 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
8 of 19
AbbVie

Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, this one is the 12th largest by enrollment, is one of 7 that started in 2015, is one of 10 in phase 3, and was the 13th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 19 studies testing ombitasvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ombitasvir

ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ombitasvir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with genotype 1 chronic hepatitis C virus infection.

03

Conditions studied

  • Chronic Hepatitis C
  • Cirrhosis
  • Hepatitis C Virus

Keywords

  • Chronic Hepatitis C
  • Interferon-Free
  • Hepatitis C Genotype 1
  • Hepatitis C Virus
  • Hepatitis C
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • US military veteran currently receiving healthcare through the Veterans Health Administration
  • Screening laboratory result indicating virus (HCV), genotype 1-infection
  • Positive for hepatitis C antibodies or HCV RNA at least 6 months before Screening, and HCV RNA > 1,000 IU/mL at the time of Screening or HCV RNA > 1,000 IU/mL at the time of Screening with a liver consistent with chronic HCV-infection (or a liver biopsy performed prior to enrollment with evidence of chronic hepatitis C disease)

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Positive test result for surface antigen (HbsAg) or anti- antibodies (HIV Ab)
  • Prior or current use of any or commercially available anti- agents other than IFN, pegIFN, RBV or sofosbuvir
  • Any current or past clinical evidence of B or C classification
  • Confirmed presence of hepatocellular carcinoma indicated on imaging techniques within 3 months prior to Screening or on an ultrasound performed at Screening for participants with cirrhosis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    3-DAA ± RBV for 12 or 24 weeks

    3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: Ribavirin

Interventions

  • Drugombitasvir/paritaprevir/ritonavir and dasabuvir

    Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir

    Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

    Also known as: Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333

  • Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backwards imputation were imputed as nonresponders.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Participants With Virologic Failure During Treatment

    On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment.

    Time frame: up to 12 weeks (for 12-week treatment group) or up to 24 weeks (for 24-week treatment group

  2. Percentage of Participants With Post-treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.

    Time frame: From the end of treatment through 12 weeks after the last dose of study drug

  3. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backwards imputation were imputed as nonresponders.

    Time frame: 12 weeks after the last actual dose of study drug

07

Results

Posted Aug 30, 2017

Participant flow

Participant flow — Overall Study
Milestone3-DAA ± RBV for 12 or 24 Weeks
Started99
Completed92
Not completed7
Withdrew: Adverse event1
Withdrew: Withdrew consent2
Withdrew: Lost to follow-up3
Withdrew: Other1

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backwards imputation were imputed as nonresponders.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
percentage of participants3-DAA ± RBV for 12 or 24 Weeks
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)93.9 (87.4 to 97.2)
SecondaryPercentage of Participants With Virologic Failure During Treatment

On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment.

Time frame:
up to 12 weeks (for 12-week treatment group) or up to 24 weeks (for 24-week treatment group
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure During Treatment
percentage of participants3-DAA ± RBV for 12 or 24 Weeks
Percentage of Participants With Virologic Failure During Treatment1.0 (0.2 to 5.5)
SecondaryPercentage of Participants With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.

Time frame:
From the end of treatment through 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participants3-DAA ± RBV for 12 or 24 Weeks
Percentage of Participants With Post-treatment Relapse2.2 (0.6 to 7.7)
SecondaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backwards imputation were imputed as nonresponders.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders
percentage of participants3-DAA ± RBV for 12 or 24 Weeks
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders95.8 (86.0 to 98.8)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 16 weeks for participants treated for 12 weeks and up to 28 weeks for participants treated for 24 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3-DAA ± RBV for 12 or 24 Weeks—7/99 (7.1%)58/99 (58.6%)
Most frequent serious events
Most frequent serious events
Event3-DAA ± RBV for 12 or 24 Weeks
MYOCARDIAL INFARCTIONCardiac disorders1/99
PANCREATITISGastrointestinal disorders1/99
DRUG INTERACTIONGeneral disorders1/99
CHOLANGITISHepatobiliary disorders1/99
CHOLECYSTITISHepatobiliary disorders1/99
GASTROENTERITIS VIRALInfections and infestations1/99
PNEUMONIAInfections and infestations1/99
DEPRESSIVE SYMPTOMPsychiatric disorders1/99
MENTAL STATUS CHANGESPsychiatric disorders1/99
SCHIZOPHRENIAPsychiatric disorders1/99
Most frequent other events
Showing 10 of 15
Most frequent other events
Event3-DAA ± RBV for 12 or 24 Weeks
FATIGUEGeneral disorders28/99
HEADACHENervous system disorders20/99
NAUSEAGastrointestinal disorders15/99
INSOMNIAPsychiatric disorders10/99
PRURITUSSkin and subcutaneous tissue disorders10/99
DIARRHOEAGastrointestinal disorders9/99
DIZZINESSNervous system disorders8/99
COUGHRespiratory, thoracic and mediastinal disorders8/99
HAEMOGLOBIN DECREASEDInvestigations6/99
ARTHRALGIAMusculoskeletal and connective tissue disorders6/99

Baseline characteristics

Age, Continuous
Age, Continuous(years)3-DAA ± RBV for 12 or 24 Weeks
Mean61.5 ± 5.90
Sex: Female, Male
Sex: Female, Male(Participants)3-DAA ± RBV for 12 or 24 Weeks
Female4
Male95
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Aug 2016, 15 months.

Results were first posted in Aug 2017, 1 year after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2015
First posted
May 13, 2015
StartActual
May 13, 2015
Primary completionActual
Aug 22, 2016
CompletionActual
Oct 31, 2016
Results first posted
Aug 30, 2017
Last update
Oct 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02442284
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 13, 2015
Start date
May 13, 2015
Primary completion
Aug 22, 2016
Completion
Oct 31, 2016
Results posted
Aug 30, 2017
Last update
Oct 16, 2017

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ribavirin

Start the discussion